by Richard Daverman, PhD
February 3, 2014 -- Abiomed has been granted China approval for two versions of its minimally invasive heart pump, the Impella 2.5 and Impella 5.0. Abiomed is a Massachusetts-based market of cardiac devices. The Impellas, which are designed to provide temporary assistance to the heart, are inserted into the left ventricle via a catheter and pump blood into the aorta. The devices are used as temporary support for patients who are otherwise too weak to undergo an interventional cardiac procedure. More details....
Stock Symbol: (NSDQ: ABMD)
Help employers find you! Check out all the jobs and post your resume.
